VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

L. amazonensis CP Protein Vaccine
Vaccine Information
  • Vaccine Name: L. amazonensis CP Protein Vaccine
  • Target Pathogen: Leishmania amazonensis
  • Target Disease: Leishmaniasis
  • Vaccine Ontology ID: VO_0004199
  • Type: Subunit vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: A 500 bp fragment encoding an isoform of cysteine proteinase (CP) from Leishmania (Leishmania) amazonensis was subcloned and expressed in the pHis vector, resulting in a recombinant protein of 24 kDa, rLacys24 (Fedeli et al., 2010).
  • CP cysteine proteinase gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: subcutaneous injection
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Female BALB/c mice (six per group) were immunized thrice with a 2 week interval with 25 μg of rLacys24 plus complete Freund’s adjuvant (CFA) by the subcutaneous route in the base of the tail. Control animals received PBS or only adjuvant (Fedeli et al., 2010).
  • Challenge Protocol: Two weeks after the last dose animals were challenged with 2.5 × 10^5 L. (L.) amazonensis amastigotes in PBS in the hind footpad (Fedeli et al., 2010).
  • Efficacy: Immunization of BALB/c mice with rLacys24 plus CFA adjuvant resulted in a low but significant decrease of foot lesions after challenge with L. (L.) amazonensis compared to those exhibited by control mice (Fedeli et al., 2010).
References
Fedeli et al., 2010: Fedeli CE, Ferreira JH, Mussalem JS, Longo-Maugéri IM, Gentil LG, dos Santos MR, Katz S, Barbiéri CL. Partial protective responses induced by a recombinant cysteine proteinase from Leishmania (Leishmania) amazonensis in a murine model of cutaneous leishmaniasis. Experimental parasitology. 2010; 124(2); 153-158. [PubMed: 19735658].